Clinical trial
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent…
NCT00354601 · Wake Forest University Health Sciences, Other · Terminated
Key facts
| NCT number | NCT00354601 |
|---|---|
| Title | Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer |
| Official title | A Phase II Study of Weekly Docetaxel and Capecitabine for Persistent or Recurrent Platinum Resistant Epithelial Carcinoma of the Ovary, Fallopian Tube or Peritoneum |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, docetaxel |
| Enrollment | 2 |
| Start date | Jan 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jul 20, 2006 |
| Last update posted | Aug 30, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: